First In Human Study for Small to Medium-sized Abdominal Aortic Aneurysm (AAA)

Inclusion Criteria: * Male or Female aged 18 years or older * Subject can understand the purpose of the trial, voluntarily participate in the trial and sign the informed consent and is willing to complete the follow-up according to the requirements of the protocol. * Infrarenal non-aneurysmal neck ≥15mm in length * Aortic neck diameters ≤ 29mm * Infrarenal neck angulation ≤ 60° * Abdominal aneurysm from 3.5 cm to 5.0 cm. * Overall AAA treatment length (distal renal to distal inferior margin of the aneurysm) not to exceed 10 cm * Patient iliac or femoral arteries access vessels' size and morphology allow endovascular access of 14F introducer sheaths and catheters. * Subject has \> one-year life expectancy. * Subject is American Society of Anesthesiology (ASA) grade 1 through 3, inclusive. * Subject is able and willing to comply with 1, 3, 6, 12, 24 and 36-month follow-up. Exclusion Criteria: * Subject has an acutely ruptured or leaking or emergent aneurysm. * Subject has a dissecting aneurysm. * Subject has a mycotic or infected aneurysm. * Subject has current vascular injury due to trauma. * Subject's aneurysm is thoracic or suprarenal. * Previous surgical or endovascular aneurysm repair for abdominal aortic aneurysm. * Subject has thrombus, calcification, and/or plaque that may compromise delivery. * Subject has had a myocardial infarction within six (6) months prior to enrollment. * Subject has current angina or other active cardiac condition such as congestive heart failure, untreated or worsening atrial arrhythmia, ventricular arrhythmia, or valvular disease. * Subject has undergone other major surgery within the 30 days prior to enrollment. * Subjects with any transient ischemic attack (TIA) or ischemic stroke within 3 months. * Known allergy to polyester or contrast material that cannot be pretreated. * Subject is morbidly obese or has other clinical conditions that severely inhibit X-ray visualization of the aorta. * Subject has connective tissue disease (e.g., Marfan syndrome, Eaton syndrome, or Bessel's disease). * Known contraindication to undergoing angiography or anticoagulation. * Subject has active systemic infection. * Subject is participating in another research study. * Subject has other medical, social, or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment and the procedures and evaluations pre- and post-treatment. * Women of childbearing potential who are pregnant, lactating, or planning to become pregnant during the course of the trial. * Subject has dialysis dependent renal failure or baseline serum creatinine level \>2.0mg/dl. * Subjects with liver dysfunction: alanine transaminase (ALT) or aspartate transaminase (AST) is five times higher than the normal upper limit; serum total bilirubin (STB) is two times higher than the normal upper limit. * Subjects who are not suitable for endovascular treatment, as judged by the investigator.